Welcome to LookChem.com Sign In|Join Free

CAS

  • or
DihydrosesaMin is a chemical compound derived from rosmarinic acid, a polyphenol found in various plants, including rosemary. It is known for its antioxidant and anti-inflammatory properties and has been studied for its potential therapeutic applications in the treatment of neurological disorders, cardiovascular diseases, diabetes, and cancer therapy.

83708-70-7 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 83708-70-7 Structure
  • Basic information

    1. Product Name: DihydrosesaMin
    2. Synonyms: DihydrosesaMin;(2R,3S,4S)-2-(1,3-Benzodioxol-5-yl)-4-(1,3-benzodioxol-5-ylmethyl)tetrahydro-3-furanmethanol
    3. CAS NO:83708-70-7
    4. Molecular Formula: C20H20O6
    5. Molecular Weight: 356.3692
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 83708-70-7.mol
  • Chemical Properties

    1. Melting Point: 97-99℃
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: DihydrosesaMin(CAS DataBase Reference)
    10. NIST Chemistry Reference: DihydrosesaMin(83708-70-7)
    11. EPA Substance Registry System: DihydrosesaMin(83708-70-7)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 83708-70-7(Hazardous Substances Data)

83708-70-7 Usage

Uses

Used in Pharmaceutical Industry:
DihydrosesaMin is used as a therapeutic agent for the treatment of neurological disorders such as Alzheimer's disease and Parkinson's disease due to its antioxidant and anti-inflammatory properties.
Used in Cardiovascular Disease Management:
DihydrosesaMin is used as a therapeutic agent for the management of cardiovascular diseases, potentially reducing inflammation and oxidative stress associated with these conditions.
Used in Diabetes Management:
DihydrosesaMin is used as a therapeutic agent for the management of diabetes, potentially improving insulin sensitivity and reducing inflammation related to the disease.
Used in Cancer Therapy:
DihydrosesaMin is used as a potential anti-cancer agent, with studies suggesting its potential use in cancer therapy, although further research is needed to fully understand its mechanisms and efficacy.

Check Digit Verification of cas no

The CAS Registry Mumber 83708-70-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,3,7,0 and 8 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 83708-70:
(7*8)+(6*3)+(5*7)+(4*0)+(3*8)+(2*7)+(1*0)=147
147 % 10 = 7
So 83708-70-7 is a valid CAS Registry Number.

83708-70-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name ((2R,3S,4S)-2-(benzo[d][1,3]dioxol-5-yl)-4-(benzo[d][1,3]dioxol-5-ylmethyl)tetrahydrofuran-3-yl)methanol

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:83708-70-7 SDS

83708-70-7Downstream Products

83708-70-7Relevant articles and documents

A sterically encumbered photoredox catalyst enables the unified synthesis of the classical lignan family of natural products

Alfonzo, Edwin,Beeler, Aaron B.

, p. 7746 - 7754 (2019/08/30)

Herein, we detail a unified synthetic approach to the classical lignan family of natural products that hinges on divergence from a common intermediate that was strategically identified from nature's biosynthetic blueprints. Efforts toward accessing the common intermediate through a convergent and modular approach resulted in the discovery of a sterically encumbered photoredox catalyst that can selectively generate carbonyl ylides from electron-rich epoxides. These can undergo concerted [3 + 2] dipolar cycloadditions to afford tetrahydrofurans, which were advanced (2-4 steps) to at least one representative natural product or natural product scaffold within all six subtypes in classical lignans. The application of those synthetic blueprints to the synthesis of heterolignans bearing unnatural functionality was demonstrated, which establishes the potential of this strategy to accelerate structure-activity-relationship studies of these natural product frameworks and their rich biological activity.

Efficient rhodium-catalyzed conjugate addition of arylboronic acids to unsaturated furano esters for the highly stereoselective synthesis of four natural trisubstituted furanolignans

Mondiere, Aurelie,Pousse, Guillaume,Bouyssi, Didier,Balme, Genevieve

scheme or table, p. 4225 - 4229 (2011/02/24)

Four natural lignans, (±)-dihydrosesamin (1a), (±)- lariciresinol methyl ether (1b, (±)-sanshodiol methyl ether (1c) and (±)-acuminatin methyl ether (1d), were prepared stereoselectively in five steps from a 4-(arylmethylene)-2-methoxy-tetrahydrofuran der

Reagent-controlled stereoselective synthesis of lignan-related tetrahydrofurans

Miles, Steven M.,Marsden, Stephen P.,Leatherbarrow, Robin J.,Coates, William J.

, p. 6874 - 6882 (2007/10/03)

The reaction of ring-closing metathesis-derived cyclic allylsiloxanes 3 with aldehydes in the presence of a Lewis acid gives 2,3,4-trisubstituted tetrahydrofurans related to the furanolignan family of natural products. The reactions proceed with complete

Stereoselective synthesis of trisubstituted tetrahydrofurans by radical cyclisation reaction using a hypophosphite salt. Application to the total synthesis of (±)-dihydrosesamin

Chandra Roy, Subhas,Guin, Chandrani,Kumar Rana, Kalyan,Maiti, Gourhari

, p. 2435 - 2439 (2007/10/03)

The stereoselective synthesis of tetrahydrofurans has been achieved from bromoalkynes and bromoalkenes by intramolecular radical cyclisation using a hypophosphite salt. This radical cyclisation strategy has successfully been applied to the total synthesis

Short and stereoselective total synthesis of furano lignans (±)-dihydrosesamin, (±)-lariciresinol dimethyl ether, (±)-acuminatin methyl ether, (±)-sanshodiol methyl ether, (±)-lariciresinol, (±)-acuminatin, and (±)-lariciresinol

Roy, Subhas Chandra,Rana, Kalyan Kumar,Guin, Chandrani

, p. 3242 - 3248 (2007/10/03)

Intramolecular radical cyclization of suitably substituted epoxy ethers 4a-g using bis(cyclopentadienyl)titanium(III) chloride as the radical source resulted in trisubstituted tetrahydrofurano lignans and 2,6-diaryl-3,7-dioxabicyclo [3.3.0] octane lignans depending on the reaction conditions. The titanium(III) species was prepared in situ from commercially available titanocene dichloride and activated zinc dust in THF. Upon radical cyclization followed by acidic workup, epoxy olefinic ethers 4a-g afforded furano lignans dihydrosesamin 1a, lariciresinol dimethyl ether lb, acuminatin methyl ether le, and sanshodiol methyl ether 1g directly and lariciresinol 1h, acuminatin li, and lariciresinol monomethyl ether 1j after removal of the benzyl protecting group by controlled hydrogenolysis of the corresponding cyclized products. The furofuran lignans sesamin 2a, eudesmin 2b, and piperitol methyl ether 2e were also prepared directly by using the same precursors 4a-f on radical cyclization followed by treatment with iodine and pinoresinol 2h, piperitol 2i, and pinoresinol monomethyl ether 2j after controlled hydrogenolysis of the benzyl protecting group of the corresponding cyclized products. Two naturally occurring acyclic lignans, secoisolariciresinol 5h and secoisolariciresinol dimethyl ether 5b, have also been prepared by exhaustive hydrogenolysis of 2h and 2b, respectively.

Short and stereoselective total synthesis of (±)-dihydrosesamin and (±)-acuminatin methyl ether by radical cyclisation of epoxides using a transition-metal radical source

Rana,Guin,Roy

, p. 1249 - 1250 (2007/10/03)

Short, efficient and stereoselective synthesis of a furano lignans, (±)- Dihydrosesamin and (±)-Acuminatin Methyl Ether has been achieved in good overall yield through the radical cyclisation of epoxides using a Ti(III) reagent as the radical initiator.

Radical cyclisation route to furanolignans: short and stereoselective synthesis of (+/-)-dihydrosesamin and (+/-)-lariciresinol

Maiti, Gourhari,Adhikari, Sankar,Roy, Subhas Chandra

, p. 927 - 930 (2007/10/02)

The furanolignans, (+/-)-dihydrosesamin 3a, and (+/-)-lariciresinol 4 have been synthesised by a very short and stereoselective route in good overall yield using a radical cyclisation as the key step.The radical precursor 2, prepared from the easily acces

Short and stereoselective synthesis of (±)-dihydrosesamin by a radical cyclisation reaction

Maiti,Adhikari,Roy

, p. 3985 - 3986 (2007/10/02)

A short and stereoselective synthesis of (±)-dihydrosesamin 1 has been achieved from 2 by intramolecular radical cyclisation reaction in good overall yield.

Stereospecific Synthesis of the 2,3-trans-3,4-cis Trisubstituted Tetrahydrofuran Lignan(+/-)-Dihydrosesamin

Stevens, David R.,Whiting, Donald A.

, p. 633 - 637 (2007/10/02)

It is shown that the stereochemistry of additions to the 3-arylidene lactones 3 and 9 is controlled by the 5- rather than the 4-substituent; synthesis of the 2,3-trans-3,4-cis lignan dihydrosesamin 11b (R = H) thus requires use of the 4,5-cis- lactone 8,

Synthesis of the Lignan (+/-)-Dihydrosesamin: Problems of Stereocontrol in the Formation of 2,3,4-Trisubstituted Tetrahydrofurans and Tetrahydrofuranones

Stevens, David R.,Whiting, Donald A.

, p. 425 - 426 (2007/10/02)

It is shown that the stereochemistry of addition reactions to 3-arylidene lactones (3) and (9) is controlled by the 5- rather than the 4-substituent: synthesis of the 2,3-trans 3,4-cis lignan dihydrosesamin (11) thus requires use of the 4,5-cis lactone (8), with epimerisation at C-2 following establishment of 3,4-cis geometry.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 83708-70-7